^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Promacta (eltrombopag)

    i
    Other names: SB-497115, SB-497115-GR, 497115, ETB-115, SB497115, SB 497115, SB497115GR, SB 497115 GR, ETB115, ETB 115
    Company:
    GSK, Novartis, Royalty
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    5d
    Aplastic anaemia with small paroxysmal nocturnal haemoglobinuria clones developing during osimertinib therapy for non-small cell lung cancer. (PubMed, Leuk Res Rep)
    We diagnosed the patient with moderately severe AA and observed hematopoietic recovery following treatment with anabolic steroids and eltrombopag...Cyclosporine and romiplostim treatment were effective, allowing for outpatient management. In the two cases described herein, a small number of PNH-phenotype cells were confirmed. The clinical importance of the small PNH-phenotype populations and the mechanism underlying AA during OSIM therapy remain unclear and warrant further investigation.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive
    |
    Tagrisso (osimertinib) • Promacta (eltrombopag) • cyclosporine • Nplate (romiplostim)
    21d
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2030 --> Mar 2030 | Trial primary completion date: Dec 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    25d
    Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=174, Recruiting, Associazione Qol-one | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Promacta (eltrombopag)
    1m
    rhTPO Dose Escalation vs Eltrombopag Switch in ITP (clinicaltrials.gov)
    P=N/A, N=112, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    Promacta (eltrombopag)
    1m
    Severe aplastic anemia concurrent with lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: A case report. (PubMed, Intern Med)
    Treatment prioritized AA with cyclosporine and eltrombopag. Subsequently, the LPL/WM was treated with rituximab monotherapy...Although AA is a diagnosis of exclusion, its coexistence with lymphoma is rare. This case highlights the diagnostic and therapeutic complexity of AA and LPL/WM overlap and suggests that prioritizing the treatment of AA may lead to better outcomes.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • Promacta (eltrombopag) • cyclosporine
    1m
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=80, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Recruiting | N=39 --> 80
    Enrollment open • Enrollment change
    |
    Promacta (eltrombopag) • cyclosporine
    2ms
    CETB115G1401: Revolade Tablets Specified Drug-use Survey (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2029 --> Oct 2028 | Trial primary completion date: Mar 2029 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag)
    2ms
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    2ms
    A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia (clinicaltrials.gov)
    P=N/A, N=13, Completed, Novartis Pharmaceuticals
    New trial
    |
    Promacta (eltrombopag)
    3ms
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=80 --> 39
    Enrollment closed • Enrollment change
    |
    Promacta (eltrombopag) • cyclosporine
    4ms
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=80, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: May 2028 --> Dec 2033
    Trial completion date
    |
    Promacta (eltrombopag) • cyclosporine
    4ms
    TQZ3469-BE-01: Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State (clinicaltrials.gov)
    P=N/A, N=36, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Mar 2020 --> Mar 2023
    Trial initiation date
    |
    Promacta (eltrombopag)